Indivior's SUBLOCADE Prior Approval Supplement Receives FDA Priority Review With PDUFA Date Set For Feb 7, 2025
Portfolio Pulse from Benzinga Newsdesk
Indivior's SUBLOCADE has received FDA priority review for a potential label expansion, with a PDUFA date set for February 7, 2025. The expansion could include rapid induction and alternative injection sites.
October 07, 2024 | 3:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Indivior's SUBLOCADE is under FDA priority review for a label expansion, which could enhance its marketability by including rapid induction and new injection sites. The PDUFA date is set for February 7, 2025.
The FDA priority review suggests a significant potential for SUBLOCADE's market expansion, which could positively impact Indivior's stock. The inclusion of rapid induction and alternative injection sites could make the product more versatile and appealing to healthcare providers.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100